CA
NZ
UK
AU
IND
US
…
Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 "VEGFR-3", currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
| Income before tax | -148.45M | -99.12M | -50.28M | -17.22M | -24.89M |
| Net income | -142.52M | -92.82M | -45.34M | -11.36M | -14.64M |
| Selling general administrative | 27.84M | 17.83M | 13.72M | 4.00M | 3.07M |
| Selling and marketing expenses | - | - | - | - | 0.29M |
| Gross profit | 0.11M | 0.09M | 0.07M | - | - |
| Reconciled depreciation | 0.10M | 0.08M | 0.11M | 0.14M | 0.03M |
| Ebit | -146.80M | -93.72M | -28.63M | -17.21M | -25.99M |
| Ebitda | -146.70M | -93.65M | -28.52M | -17.11M | -25.97M |
| Depreciation and amortization | 0.10M | 0.08M | 0.11M | 0.10M | 0.02M |
| Operating income | -146.80M | -93.72M | -28.63M | -17.21M | -25.99M |
| Other operating expenses | 150.13M | 96.63M | 39.71M | 17.48M | 25.73M |
| Interest expense | 13.46M | 0.24M | 21.65M | 0.01M | 1.09M |
| Tax provision | -5.93M | -6.30M | -4.94M | -8.53M | -14.64M |
| Interest income | 3.23M | 0.24M | 0.37M | 0.72M | 0.76M |
| Net interest income | -10.23M | 0.24M | 0.37M | 0.72M | 0.76M |
| Income tax expense | -5.93M | -6.30M | -4.94M | -5.86M | -10.25M |
| Total revenue | 0.11M | 0.09M | 0.07M | - | - |
| Total operating expenses | 150.13M | 96.63M | 39.71M | 17.48M | 25.73M |
| Total other income expense net | 11.81M | -5.39M | -21.65M | -0.01M | 1.09M |
| Net income from continuing ops | -142.52M | -92.82M | -45.34M | -16.53M | -20.91M |
| Net income applicable to common shares | -142.52M | -92.82M | -45.34M | -16.53M | -20.91M |
| Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
| Total assets | 98.64M | 60.05M | 138.41M | 49.40M | 26.38M |
| Other current assets | - | 8.72M | 14.39M | 6.19M | 10.55M |
| Total liab | 104.40M | 12.07M | 3.12M | 4.86M | 4.58M |
| Total stockholder equity | -5.76M | 47.98M | 135.29M | 44.53M | 21.79M |
| Other current liab | 0.75M | 0.64M | 0.58M | 0.16M | 0.43M |
| Common stock | 320.88M | 235.28M | 234.15M | 111.38M | 79.15M |
| Capital stock | 320.88M | 235.28M | 234.15M | 111.38M | 79.15M |
| Retained earnings | -359.37M | -216.94M | -124.12M | -70.49M | -60.27M |
| Other liab | 0.01M | 0.03M | 0.02M | 0.04M | 0.02M |
| Other assets | 0.05M | 0.11M | 0.17M | - | 0.00M |
| Cash | 89.19M | 44.63M | 118.19M | 42.62M | 15.08M |
| Total current liabilities | 18.65M | 12.04M | 3.11M | 4.75M | 4.56M |
| Current deferred revenue | - | - | - | 0.48M | - |
| Net debt | -89.01M | -44.63M | -118.08M | -42.43M | -15.08M |
| Short term debt | 0.10M | - | 0.11M | 0.10M | - |
| Short long term debt total | 0.18M | - | 0.11M | 0.18M | - |
| Other stockholder equity | 32.73M | 47977.14M | 25.26M | 0.00M | 0.00M |
| Property plant equipment | 0.20M | 0.03M | 0.12M | 0.28M | 0.05M |
| Total current assets | 98.39M | 59.91M | 138.12M | 49.00M | 25.84M |
| Long term investments | - | - | 0.00M | 0.29M | 0.71M |
| Net tangible assets | -5.85M | 47.98M | 135.29M | 64.81M | 31.12M |
| Net receivables | 6.56M | 6.56M | 5.54M | 0.20M | 0.21M |
| Accounts payable | 17.80M | 11.40M | 2.42M | 4.01M | 4.13M |
| Accumulated other comprehensive income | 32.73M | 29.64M | 25.26M | 3.64M | 2.91M |
| Common stock total equity | - | - | 234.15M | 162.10M | 113.02M |
| Non currrent assets other | 0.05M | 0.11M | 0.17M | 0.00M | - |
| Non current assets total | 0.26M | 0.14M | 0.29M | 0.39M | 0.54M |
| Capital lease obligations | 0.18M | 0.00M | 0.11M | 0.27M | - |
| Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
| Investments | -0.02M | -0.02M | 0.67M | 0.48M | 0.32M |
| Change to liabilities | 7.30M | 8.51M | -1.55M | -0.06M | -1.43M |
| Total cashflows from investing activities | -0.02M | -0.02M | 0.66M | 0.48M | 0.32M |
| Net borrowings | 84.43M | -0.09M | -0.09M | -0.10M | -0.10M |
| Total cash from financing activities | 167.29M | 0.17M | 116.94M | 33.66M | 8.85M |
| Change to operating activities | 6.28M | 5.85M | -14.19M | 0.06M | -0.07M |
| Net income | -142.52M | -92.82M | -45.34M | -11.36M | -14.64M |
| Change in cash | 44.56M | -73.56M | 75.54M | 27.82M | -7.69M |
| Begin period cash flow | 44.63M | 118.19M | 42.65M | 14.80M | 22.77M |
| End period cash flow | 89.19M | 44.63M | 118.19M | 42.62M | 15.08M |
| Total cash from operating activities | -120.61M | -71.33M | -45.55M | -6.03M | -16.94M |
| Issuance of capital stock | 81.82M | 0.00M | 105.48M | 33.72M | 8.85M |
| Depreciation | 0.10M | 0.08M | 0.11M | 0.14M | 0.03M |
| Change to account receivables | 0.38M | 0.31M | -0.37M | 0.01M | 0.10M |
| Other cashflows from financing activities | 85.54M | 0.26M | 11.55M | -0.07M | 0.22M |
| Change to netincome | 7.86M | 6.74M | 15.80M | 7.58M | -1.91M |
| Capital expenditures | 0.02M | 0.02M | 0.01M | 0.00M | 0.01M |
| Change in working capital | 13.95M | 14.66M | -16.11M | - | - |
| Stock based compensation | 5.83M | 5.25M | 3.90M | - | - |
| Other non cash items | 7.95M | 7.79M | 16.85M | 11.21M | 14.61M |
| Free cash flow | -120.63M | -71.35M | -45.56M | -6.04M | -16.95M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| NVO Novo Nordisk A/S |
0.45 1.12% |
40.45 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-5.73 1.03% |
553.15 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
33.37 3.60% |
961.26 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 "VEGFR-3", currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.
| Name | Title | Year Born |
|---|---|---|
| Dr. Megan Baldwin M.A.I.C.D., MAICD, Ph.D. | MD, CEO & Exec. Director | 1974 |
| Ms. Judith J. Robertson B.A., M.B.A. | Chief Commercial Officer | 1960 |
| Dr. Joel Naor M.D., MBA, MSc | Chief Medical Officer | NA |
| Ms. Karen Adams CPA | VP of Fin. & Company Sec. | 1971 |
| Mr. Timothy E. Morris CPA, CPA | Chief Financial Officer | 1961 |
| Ms. Annie Lee | Fin. & Operations Mang. | NA |
| Dr. Michael Gerometta Ph.D. | Head of Chemistry, Manufacturing & Controls Devel. | 1964 |
| Mr. Bruno Gagnon BPHARM, M.Sc. | Sr. VP of Global Clinical Operations | NA |
| Dr. Ian Leitch | Director of Clinical Research | 1963 |
| Dr. James Goding | Independent Consultant | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-0.09%
Communication Services
+0.21%
Consumer Cyclical
+1.14%
Consumer Defensive
+0.88%
Energy
-2.61%
Financial Services
+0.70%
Financials
+0.41%
Healthcare
-0.75%
Industrials
+0.35%
Real Estate
+0.57%
Technology
-1.17%
Utilities
+0.05%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...